Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Two China-US Life Science Investment Firms, WuXi Ventures and Frontline, Will Merge

publication date: May 22, 2017
Two prominent China-US healthcare investment firms plan to join forces: WuXi Healthcare Ventures and Frontline BioVentures will merge to form 6 Dimensions Capital. Together, the two firms have almost $800 million under management. 6 Dimensions plans to continue growing by starting two new funds, one dollar-based and the other renminbi. Dr. Ge Li, Chairman and CEO of WuXi AppTec, will serve as Chairman of 6 Dimensions, and Dr. Leon Chen, Managing Partner of Frontline, will be the firm's CEO. WuXi Ventures has focused on innovative US startups, while Frontline is an established China venture firm. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital